.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
QuintilesIMS
UBS
Chubb
Baxter
Johnson and Johnson
Medtronic
Teva
Dow
Cipla

Generated: November 19, 2017

DrugPatentWatch Database Preview

Ipsen Pharma Company Profile

« Back to Dashboard

What is the competitive landscape for IPSEN PHARMA, and when can generic versions of IPSEN PHARMA drugs launch?

IPSEN PHARMA has one approved drug.

There is one US patent protecting IPSEN PHARMA drugs.

There are sixty-four patent family members on IPSEN PHARMA drugs in seventeen countries and two supplementary protection certificates in two countries.

Summary for Ipsen Pharma

International Patents:64
US Patents:1
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-003Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-001Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-001Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-002Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-003Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-003Aug 30, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-002Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-002Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-001Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-003Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Ipsen Pharma

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,582,591 Delivery of solid drug compositions► Subscribe
5,837,276 Apparatus for the delivery of elongate solid drug compositions► Subscribe
6,306,420 Methods and apparatus for the delivery of solid drug compositions► Subscribe
5,660,846 Methods and apparatus for the delivery of solid drug compositions► Subscribe
5,616,123 Delivery of solid drug compositions► Subscribe
6,142,972 Method and apparatus for the delivery of elongate solid drug compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ipsen Pharma Drugs

Country Document Number Estimated Expiration
European Patent Office0953362► Subscribe
China101590011► Subscribe
Hong Kong1040631► Subscribe
Spain2141956► Subscribe
Australia713066► Subscribe
South Korea20030096434► Subscribe
Austria280599► Subscribe
Portugal778785► Subscribe
South Africa9601904► Subscribe
Denmark0779805► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Ipsen Pharma Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
037Luxembourg► Subscribe91037, EXPIRES: 20160511
2002 00032Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Teva
Fish and Richardson
QuintilesIMS
Healthtrust
US Army
Boehringer Ingelheim
Covington
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot